The COVID-19 pandemic caused emotional challenges for many people with myasthenia gravis (MG) in Australia, but how well their disease was treated or how well their symptoms were kept under control weren’t affected, a survey study finds. “As we continue to live with COVID-19, clinicians should consider its various…
News
Tofacitinib, an approved medication for some types of inflammatory arthritis and inflammatory bowel disease, may also help treat myasthenia gravis (MG), a new study done in an animal model and cell samples suggests. Treatment with tofacitinib was found to ease muscle weakness and weight loss in a rat model…
Top-line results from a Phase 3 clinical trial of batoclimab in people with generalized myasthenia gravis (gMG) are expected by the end of March, Roivant, which is developing the antibody therapy through its subsidiary Immunovant, reported. The company said that trial findings will inform further decisions regarding next…
People with myasthenia gravis (MG) face a mean annual healthcare cost of nearly $16,000, according to a survey of MG patients and their caregivers. Medications and treatments accounted for most out-of-pocket expenses (27%), followed by insurance premiums (20%), diagnosis (15%), and caregiving assistance (14%). “Disseminating the findings of this…
People newly diagnosed with myasthenia gravis (MG) in England experience a high disease burden, with about two-thirds having at least one exacerbation, or an episode of disease worsening, and approximately half having one MG-related hospitalization. That’s according to a new study led by researchers from the pharmaceutical company…
Enspryng (satralizumab), tested by Chugai Pharmaceutical as a treatment for generalized myasthenia gravis (gMG), eased disease symptoms and made daily life easier when used in addition to standard of care therapy over six months, but its clinical benefit was somewhat limited. These data from LUMINESCE (NCT04963270), a…
People with myasthenia gravis (MG) have a higher risk of developing cancer in organs other than the thymus, particularly in the skin and gastrointestinal tract, than people without the disease, according to a study. The incidence of such cancers tended to be higher in the five years before and…
Most people with very late-onset myasthenia gravis (MG) — patients in whom symptoms start to manifest at age 65 or older — who are positive for self-reactive antibodies against acetylcholine receptors, or AChRs, show significant clinical improvements within two years of disease onset, according to a new study…
Cartesian Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the design of the planned Phase 3 AURORA trial that will test its investigational cell therapy Descartes-08 in people with myasthenia gravis (MG). The FDA, under its special protocol assessment process, provided written agreement…
Nipocalimab outperformed a placebo at easing the severity of generalized myasthenia gravis (gMG) in a Phase 3 clinical trial called Vivacity-MG3. Full results from the trial were detailed in the study, “Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3,…
Recent Posts
- Women with MG have higher risk of complications during pregnancy
- This year, I’m pushing boundaries in how I live with MG
- Early rituximab treatment may improve long-term outcomes in gMG
- Vyvgart plus low-dose steroids is safer treatment for severe gMG: Study
- Guest Voice: Don’t let fear hold you back from living fully with MG